AURORA 2 Project Collaboration
Metastatic Breast Cancer
Phase 2Active
Key Facts
About Seqalis
Seqalis is a private, revenue-generating service provider in the diagnostics and genomics sector, operating a specialized laboratory in Belgium. It serves as a contract research organization (CRO) and testing partner for biotech and pharmaceutical companies, offering a suite of technical services including sequencing, histopathology, and custom assay development. The company is actively involved in high-profile research collaborations, such as the AURORA breast cancer project, indicating its role in supporting clinical and translational research. Its business model is focused on providing fee-for-service laboratory analyses and scientific advisory, rather than developing its own therapeutic products.
View full company profileTherapeutic Areas
Other Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ZetaMAST (Zeta-MBC-005) | Zetagen Therapeutics | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Vectorized-VX-765 | Atlanthera | Research |
| BPI-1178 (Eciruciclib) | Beta Pharma | Phase 3 |
| Herzuma® | Celltrion | Marketed |
| Eftilagimod alfa (efti) | Immutep | Phase IIb |
| (Z)-endoxifen | Atossa Therapeutics | Phase 1/2 |
| Bria-IMT™ + CPI | BriaCell Therapeutics | Phase 3 |
| Bria-OTS™ (Bria-BRES™) | BriaCell Therapeutics | Phase 1/2 |